Reference
Delea TE, et al. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States. PharmacoEconomics : 20 Jun 2019. Available from: URL: http://doi.org/10.1007/s40273-019-00812-6
Rights and permissions
About this article
Cite this article
Blinatumomab cost effective versus inotuzumab ozogamicin. PharmacoEcon Outcomes News 831, 8 (2019). https://doi.org/10.1007/s40274-019-5996-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5996-1